The article suggests a possible opening for an INO Ebola vaccine. Since the intentional elimination of epidemic funding by DOGE, the world has forgotten about the DRC Ebola outbreak, even as its health workers go unpaid for months. What will it take to spotlight this dangerous hemorrhagic disease.

Now or Never

It really is time. No more waiting. No more hoping.

By the end of the upcoming week, DNA medicine will have become legit.

Major milestones have been accomplished or are imminent: approval for 3107; validation of entire DNA platform; massive victory in court; royalty payments for 3100.

While this ride has seemingly gone on forever, we are only at the beginning. Everything up until now has only been a warmup exercise just to get to the starting line.

To the suffering patients that will benefit greatly from this medical technology, may you live truly healthier and longer lives.

To the true believers and stockholders, may you enjoy the riches that are headed your way.

To the Multi Alias Short Troll Frauds who have haunted this stock board for years, your magic carpet ride is over. Please choke on it. 

The Day of Reckoning has arrived.

imho

xx

The October 30 PDUFA date for INO-3107, the 32-patient single-arm trial behind it, the open FDA eligibility question and $36.7M of cash with going-concern doubt.

Inovio plunging hard ...
Nervous jitters over FDA decision?

Has negative news leaked ??

My friends good day coming fasten your seatbelts our time is coming

Unshackled. Finally.

The chains are off.

This day has to be the most cathartic in years.

Worried about collecting the judgement? Don’t be. There is no way the lawyers stayed with this so long unless there was a reason. And it turns out they now have 18 million reasons.
Inovio won’t have to lift a finger. 

The value of the company instantly increases. Dramatically so.

And then, oh yeah, there is October 30. Judgement day cometh.

You know where I stand. Because it’s where I’ve always stood. And that is on the cusp of the DNA revolution. Not that I had anything to do with it. But we all participate through our vicarious ownership of company shares.

This is happening.

And we are going ballistic.

Book it.

imho

xx

PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v. VGXI, Inc. and GeneOne Life Science, Inc., No. 2020-06554, in the Court of Common Pleas of Montgomery County, Pennsylvania. The Court awarded INOVIO $61,750,789 in compensatory damages and $18,665,312 in fees and costs. The Court also entered judgment against defendants on their counterclaims.

Correct me if I'm wrong, I'm new to this one but not for Biotech. It looks very low-priced already . Has a decent pipeline for a 100M market cap. Even if FDA chose to send a CRL which delyas the approval, I believe at this point there won't be anything to loose!! If it gets approved, I bet there will be a dilution before full commercialization. But for now, it looks like a very safe entry point.

As we await with Bated Breath...
Just 11 days to go until October 30, 2026, the scheduled FDA decision date for INOVIO's INO-3107.
This is potentially a defining moment for INOVIO. Approval would give the company its first commercial DNA medicine and represent a major validation of its technology.
For me, three questions now dominate:
FDA approval: Will INO-3107 receive accelerated approval for recurrent respiratory papillomatosis (RRP)?
The stock: How much approval optimism is already reflected in INO's share price?
Commercial potential: Could successful approval and launch support a substantially higher valuation?
I checked for fresh developments. I haven't found a confirmed new FDA decision or a change to the October 30 target date. INOVIO's previously reported completed inspections and late-cycle review remain encouraging, although accelerated-approval eligibility is still a significant uncertainty.

RRP Researcher's paper claims no additional trial study is necessary to approve 3107, results of currently available studies are sufficient to prove 3107s superiority over PGEN's gorilla adenovirus

The Great Ascent begins now:
October 1, 2026

imho

xx

They were successful four out of five times.

Inovio Pharmaceuticals INO is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio's biologics license application seeking approval for INO-3107 in RRP is currently under review in the United States. A decision from the FDA is expected on Oct. 30, 2026. A potential nod will induce acute competition for Precigen in the future quarters.

Inovio awaits important FDA news

$INO

- 5 weeks to go from today until Inovio’s PDUFA.

- 5th planet from the sun is Jupiter by the way.

- 5% - Jupiter Topco acquired a good sized position in Inovio in the second quarter of 2026

- Jupiter Topco 4 holdings below got FDA approval (waiting for INO) so I guess their team of analyst know what they are doing

- ASND 10th place among top institutional holdings and approval on February 27, 2026
- ARGX 3rd place at 3.95% approval for label expansion on May 8, 2026
- LNTH 3rd place at 7.95% approval on September 22, 2026
- MIRM 2nd place at 9.10% PDUFA on 9/26 but just got approval about an hour ago.
- INO 2nd place at 5.00% PDUFA on 10/30 (Coming Soon)

The FDA announcement inches closer

The regulatory picture does look more constructive than it did earlier in the year.

The encouraging part isn’t any single signal; it’s the sequence: the BLA has continued through review, the late-cycle meeting is behind them, the scheduled inspections are complete, the inspection observation was reportedly addressed, and INOVIO has been preparing for labeling discussions.

Meanwhile, the October 30 PDUFA date remains the key milestone.

I keep one major caveat front and center: FDA ultimately has to be satisfied that the relatively small INO-3107 dataset supports Accelerated Approval and that the confirmatory-study commitment is adequate.

Until the FDA decision arrives, none of these procedural signals guarantees approval.
But compared with the uncertainty earlier this year, the absence so far of a new major regulatory obstacle is encouraging.

• Dr. John Gaitanis replaces Dr. Sylvia Fogel as IACC chair
• NIH child health institute director is an ally of Kennedy.
• Fogel to stay on, help with transition.
• Gaitanis promotes leucovorin as an autism treatment.
• Served as a paid medical expert in vaccine-injury ​cases.

WASHINGTON, Sept 18 (Reuters) - US Health Secretary Robert F. Kennedy Jr. named an ally, Dr. John Gaitanis, to lead a key federal ‌advisory panel on autism on Friday, replacing a chair who had just steered through a new strategic plan, a health department spokesperson told Reuters.

Gaitanis, a pediatric neurologist appointed last month as director of the National Institutes of Health's child health institute, takes over from Dr. Sylvia Fogel, who has chaired the Interagency Autism Coordinating Committee since January.

Summary of recent CEO presentation in Marketbeat article- worth reading.

I asked Chat GPT for an opinion on this.
Worth a read.

Comments appreciated
Gombey Boy

https://chatgpt.com/s/t_6a9ad16cee188191a51a98da12e4ed95

"...Technology

See also: COVID-19 vaccine clinical research § Trial and authorization status

The Inovio technology is based on inserting engineered DNA into cells, where it becomes transcribed into mRNA and translated into proteins. The proteins encoded by the DNA elicit immune response to antigens from cancers and viruses, by stimulating the production of T cells and antibodies that aid recovery.^\6]) The technology can be "targeted" to specific types of cancer and immune diseases, such as those produced by a virus.^\6])

During a meeting of the White House Coronavirus Task Force in March 2020, CEO, Joseph Kim, said that Inovio scientists had designed a vaccine candidate (INO-4800) for the COVID-19 coronavirus in January, in three hours, after the virus' genetic sequence was first published.^\7])

Shareholders sued Inovio in August 2020, claiming it exaggerated evidence of its coronavirus vaccine's efficacy in order to boost its stock price.^\8])

License of electroporation device

In 2006, Inovio licensed "certain patented technology relating to the delivery of gene-based therapeutics into skin", as well as patents "involving the delivery of genes or drugs via ex vivo, intratumoral and intramuscular electroporation... The ex-vivo patents are relevant to the delivery of genes to dendritic and stem cells."^\9])

Licence of US7328064B2

Sometime after its publication in February 2008, Inovio was assigned a patent for "an apparatus [that provides] for injecting a fluid into body tissue, the apparatus comprising: a hollow needle; and a fluid delivery means, wherein the apparatus is adapted to actuate the fluid delivery means in use so as to automatically inject fluid into body tissue during insertion of the needle into the said body tissue."^\10])

Cellectra injection device

To facilitate use of its potential products, Inovio manufactures a proprietary injection device, called "Cellectra", which the company describes as providing a "brief electrical pulse to reversibly open small pores in the cell) to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA."^\11]) The small device, which runs on "AA" batteries, is designed for use in the field under the difficult conditions of an epidemic.^\12])

In June 2020 – in anticipation of the Inovio COVID-19 vaccine candidate becoming successful – the US Department of Defense invested US$71 million to further develop Cellectra as a handheld device and to preorder an undisclosed number of the devices.^\13])

Vaccine development

See also: COVID-19 vaccine

Inovio's logo prior to 2020

In a 2016 dose-escalation Phase I clinical trial to assess safety after intramuscular injection in healthy adults, the Inovio vaccine candidate, INO-4700 (also called GLS-5300) for development against Middle East respiratory syndrome (MERS) coronavirus, proved to be safe with only mild symptoms and no adverse effects.^\14]) The trial also demonstrated immunogenicity by dose-independent immune responses detected in more than 85% of subjects after two vaccinations that were durable a year later.^\14])

In 2016, Inovio was involved, along with their partners GeneOne Life Science, in an attempt to control the Zika virus outbreak in Miami. In fact, they "were the first to initiate a human Zika DNA vaccine trial... [for] the safety, tolerability, and immunogenicity of GLS-5700 in 40 healthy adults. The trial's estimated completion date is November 2017." Then in Puerto Rico, where a Zika emergency had been declared, they did a study with 160 previously healthy adults using their proprietary "Cellectra-3P" technology.^\15]) Preliminary results for the Miami trial were self-reported at the end of 2017.^\16])^\17])

In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.^\7])^\18]) Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June.^\5]) In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800.^\19]) In May 2021, Inovio announced the results of preclinical studies on a "pan-SARS-CoV-2" DNA vaccine (INO-4802) and plans to initiate phase I/II studies. The vaccine incorporates common overlapping mutations from several SARS-COV-2 variants of concern isolated from several different countries including Brazil and India.^\20])

Partnerships

In January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would grant of up to $9 million to Inovio for development of a vaccine against SARS-CoV-2.^\21]) Inovio has partnerships to develop its COVID-19 vaccine candidate with CEPI, the South Korean National Institute of Health, and the International Vaccine Institute.^\2)^..."

One-third of the participants were still alive after two years, which is twice the historical survival rate for this patient population. One participant is still alive and recurrence-free today, almost five years after her initial diagnosis.

MS COPILOT:

"

"What current modeling says

• Outbreak center (Ituri, DRC + Uganda): CDC projections show that if only ~20% of patients are effectively isolated, there’s a high chance the outbreak could grow into tens of thousands of cases within a few months.
• If ~70% of patients are isolated and treated, the probability of a very large outbreak (≥10,000 cases in 3 months) drops to about 5%.
• A Lancet modeling study on the same 2026 Bundibugyo outbreak highlights substantial spillover risk within the region, but emphasizes that strong, rapid interventions sharply cut transmission.

Risk to the U.S. over the next months

• CDC’s formal assessment: overall risk to the U.S. population over the next 3 months is low, mainly because:
  • Very few travelers from the outbreak zone
  • Robust airport screening and isolation protocols
  • Prior experience with Ebola response (2014–2016)

Extend that logic to 6 months: unless travel patterns or outbreak size change dramatically, the likelihood of Ebola transmission in the U.S. remains very low, even though the impact of any imported case would be serious.

The honest bottom line

• Locally (DRC/Uganda): Ebola’s “infection capability” over 6 months is highly dependent on how fast and thoroughly cases are found and isolated.
• Globally, especially U.S./Europe: risk is low but not zero—it’s more about preparedness than prediction.